Vir Biotechnology, Inc.
http://www.vir.bio
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vir Biotechnology, Inc.
Dyne Reports Progress Building Next-Generation Exon Skipping Franchise In DMD
The company reported updated data from the Phase I/II DELIVER trial testing DYNE-251 in patients with Duchenne muscular dystrophy (DMD) and announced leadership changes.
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
Finance Watch: Vir Restructures, Adds Sanofi Cancer Drugs To Clinical-Stage Pipeline
Restructuring Edition: Vir will end influenza, COVID-19 and T-cell-based viral vector platform programs to focus on clinical hepatitis and cancer assets. Also, FibroGen cut 75% of its workforce after a clinical trial failure, while Arbutus, HilleVax, Pfizer and others also announced layoffs.
Vir Hopes To Take On Gilead’s Hepcludex After Positive Early Hepatitis D Results
The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Humabs BioMed SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice